|Bid||1.3500 x 1300|
|Ask||1.5600 x 4000|
|Day's Range||1.3500 - 1.4173|
|52 Week Range||1.3500 - 3.0900|
|Beta (3Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.67|
Athersys, Inc. (ATHX) announced today that the company will host an investor day on Tuesday, May 14, 2019. The investor day will include presentations from the Company’s management team as well as experts in the fields of stroke and ARDS. Dr. David Chiu, MD, FAHA, Medical Director at the Eddy Scurlock Stroke Center at Houston Methodist Hospital will be discussing the MASTERS-2 clinical trial for stroke.
CLEVELAND, April 10, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, May 8,.
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Substantial progress over the year, advancing programs andexpanding collaboration with HEALIOS K.K. Management to host conference call at 4:30 PM EST today CLEVELAND, March.
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / Athersys, Inc. (NASDAQ: ATHX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 14, 2019, 2018 at 4:30 PM ...
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
Gil Van Bokkelen has been the CEO of Athersys, Inc. (NASDAQ:ATHX) since 1995. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look atRead More...
CLEVELAND, Feb. 14, 2019 -- Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, March 14, 2019,.
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Athersys, Inc. (ATHX) announced today summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory distress syndrome (ARDS). The study results provide further confirmation of tolerability and a favorable safety profile associated with MultiStem treatment. Importantly, MultiStem treatment was associated with lower mortality and a greater number of ventilator-free and intensive care unit (ICU) free days in the first month following diagnosis relative to patients receiving placebo.
Athersys, Inc. (ATHX) announced today the extension of HEALIOS K.K.’s (Healios) exclusive period to negotiate an option that would allow Healios to obtain a license for the development and commercialization of MultiStem therapy for certain indications in China. Healios has agreed to make a one-time $2.0 million payment in December 2018 for an extension through June 30, 2019. Furthermore, Healios may make an additional payment of $3.0 million to extend the negotiation period for another six months through December 31, 2019.
The direct benefit for Athersys Inc (NASDAQ:ATHX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...
Management to host conference call at 4:30pm EST today CLEVELAND, Nov. 06, 2018 -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the period ended.
Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).
HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from ...
A look at the shareholders of Athersys Inc (NASDAQ:ATHX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to seeRead More...